These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 31209988)

  • 1. The effect of transfer to adult transplant care on kidney function and immunosuppressant drug level variability in pediatric kidney transplant recipients.
    Fernandez HE; Amaral S; Shaw PA; Doyle AM; Bloom RD; Palmer JA; Baluarte HJ; Furth SL
    Pediatr Transplant; 2019 Sep; 23(6):e13527. PubMed ID: 31209988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients.
    Naicker D; Reed PW; Ronaldson J; Kara T; Wong W; Prestidge C
    Pediatr Nephrol; 2017 Nov; 32(11):2125-2131. PubMed ID: 28660366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients.
    Solomon S; Colovai A; Del Rio M; Hayde N
    Pediatr Nephrol; 2020 Feb; 35(2):261-270. PubMed ID: 31732803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of BMI on allograft function and survival in pediatric renal transplant recipients.
    Winnicki E; Dharmar M; Tancredi DJ; Nguyen S; Butani L
    Pediatr Nephrol; 2018 Aug; 33(8):1429-1435. PubMed ID: 29574612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High intra-patient variability of tacrolimus within post-operative 1 month predicted worse 1-year outcomes in pediatric liver transplant recipients.
    Chen F; Yong JK; Shen C; Zhou T; Feng M; Wan P; Luo Y; Lin H; Qian Y; Xia Q
    Eur J Clin Pharmacol; 2024 Jul; 80(7):1017-1027. PubMed ID: 38502358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrapatient Variability in Tacrolimus Trough Levels Over 2 Years Affects Long-Term Allograft Outcomes of Kidney Transplantation.
    Park Y; Lee H; Eum SH; Kim HD; Ko EJ; Yang CW; Chung BH
    Front Immunol; 2021; 12():746013. PubMed ID: 34659243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of intraindividual tacrolimus variability with de novo donor-specific HLA antibody development and allograft rejection in pediatric kidney transplant recipients with low immunological risk.
    Baghai Arassi M; Gauche L; Schmidt J; Höcker B; Rieger S; Süsal C; Tönshoff B; Fichtner A
    Pediatr Nephrol; 2022 Oct; 37(10):2503-2514. PubMed ID: 35166920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of converting adult kidney transplant recipients with high tacrolimus variability from twice daily immediate release tacrolimus to once daily LCP-Tacrolimus.
    Taber DJ; Bartlett F; Patel N; Sprague T; Patel S; Newman J; Andrade E; Rao N; Salas MAP; Casey M; Dubay D; Rohan V
    Clin Transplant; 2023 May; 37(5):e14941. PubMed ID: 36809653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study.
    Neu AM; Ho PL; Fine RN; Furth SL; Fivush BA
    Pediatr Transplant; 2003 Jun; 7(3):217-22. PubMed ID: 12756047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus trough levels higher than 6 ng/mL might not be required after a year in stable kidney transplant recipients.
    Jung HY; Seo MY; Jeon Y; Huh KH; Park JB; Jung CW; Lee S; Han SY; Ro H; Yang J; Ahn C; Choi JY; Cho JH; Park SH; Kim YL; Kim CD
    PLoS One; 2020; 15(7):e0235418. PubMed ID: 32614859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation.
    Song JL; Gao W; Zhong Y; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Wu H; Xu MQ; Chen ZY; Wei YG; Jiang L; Yang J
    World J Gastroenterol; 2016 Feb; 22(6):2133-41. PubMed ID: 26877618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results.
    Chamienia A; Dębska-Ślizień A; Król E; Biedunkiewicz B; Rutkowski B
    Transplant Proc; 2014 Oct; 46(8):2714-8. PubMed ID: 25380901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.
    Wojciechowski D; Chandran S; Vincenti F
    Clin Transplant; 2017 May; 31(5):. PubMed ID: 28190259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the commercial brand of tacrolimus lead to subtherapeutic trough levels and acute rejection in renal transplant recipients.
    Arreola-Guerra JM; Alberú J; Chew-Wong A; Macias DM; Hernández-Rosales J; Zuñiga-Macías L; Delgadillo-Castañeda R; Ricalde-Ríos G; Haro-Alcalde F; Villafán-Bernal JR; Ramos-Medellín CL; Reyes-Acevedo R
    Clin Transplant; 2019 Dec; 33(12):e13749. PubMed ID: 31691354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion from twice-daily to once-daily tacrolimus does not reduce intrapatient variability in tacrolimus exposure.
    Shuker N; Cadogan M; van Gelder T; Roodnat JI; Kho MM; Weimar W; Hesselink DA
    Ther Drug Monit; 2015 Apr; 37(2):262-9. PubMed ID: 25265255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.